Triazole derivatives for treatment of Alzheimer's disease

A compound of formula I:

• or a pharmaceutically acceptable salt or hydrate thereof;
• wherein:
• W represents phenyl or 5- or 6-membered heteroaryl comprising up to 3 heteroatoms selected from N, O and S, wherein the phenyl or heteroaryl is optionally fused to a further 5- or 6-membered carbocyclic, or 5- or 6-membered heterocyclic ring, W optionally bearing up to 3 R1 substituents;
• or when X is a bond W may represent CN and when X is CO W may represent a piperazin-1-yl or piperidin-1-yl ring;
• each R1 independently represents halogen, OH, amino, CF3, C1-4alkylamino, di(C1-4alkyl)amino, C2-6acylamino, N—C1-4alkoxycarbamoyl, C1-6alkoxy, C1-6alkylcarbonyl, or C1-6alkyl which is optionally substituted with OH or C1-4alkoxy;
• X represents a bond, (CH2)nO, (CH2)nNH, CO or (CH2)nNHCO where each n is 0 or 1;
• Y represents a phenyl or 5- or 6-membered heteroaryl ring which optionally bears up to 3 R2 substituents;
• or when X is a bond and W is not CN, Y may represent C≡C or a C3-6cycloalkyl ring;
• or when X is a bond or CO, Y may represent piperidin-4-yl;
• or the moiety W-X-Y may represent a fused-ring system consisting of 2 or 3 fused rings selected from the group consisting of;
• with the proviso that if X is a bond and W represents an imidazole, triazole or pyrazole ring which is linked to Y through N, then Y does not represent
• where Y1 and Y2 each independently represents N or CR2;
• each R2 independently represents halogen, CN, OH, C1-6alkyl, or C1-6alkoxy, said alkyl and alkoxy optionally having up to 3 fluorine substituents or a cyclopropyl substituent;
• Z represents CH2, CH2—CH2, O, S, NH, CH2—O, CH2—S or CH2—NH;
• R9 represent H, C1-6alkyl, C2-6alkenyl, polyfluoroC1-4alkyl, C3-6cycloalkyl, C3-6cycloalkylC1-4alkyl, C1-4alkoxyC1-4alkyl, aminoC1-4alkyl, C1-4alkylcarbonyl, polyfluoroC1-4alkylcarbonyl, C1-4alkylsulfonyl, phenyl, phenylsulfonyl, benzoyl, benzyl, naphthylmethyl or pyridylmethyl, where said phenyl and the aromatic portions of said phenylsulfonyl, benzoyl, benzyl, naphthylmethyl and pyridylmethyl optionally bear up to 3 substituents selected from halogen, C1-4alkyl, C1-4alkoxy and CF3;
• each R10 independently represents halogen, OH, C1-4alkyl, C2-4alkenyl, polyfluoroC1-4alkyl, C3-6cycloalkyl, C3-6cycloalkylC1-4alkyl, C1-4alkoxy, C1-4alkoxyC1-4alkyl, polyfluoroC1-4alkoxy, C1-4alkylcarbonyl, polyfluoroC1-4alkylcarbonyl, C1-4alkoxycarbonyl, C1-4alkylthio, C1-4alkylsulfonyl, SO2NR2, CONR2 or NR2 where each R is independently H or C1-4alkyl or the two R groups together with the nitrogen to which they are attached complete a ring selected from azetidine, pyrrolidine, piperidine, piperazine and morpholine;
• or phenyl or benzyl either of which optionally is substituted with halogen, C1-4alkyl, C1-4alkoxy or CF3;
• or two R10 groups attached to adjacent ring positions optionally complete a fused benzene, naphthalene, cyclopentane, cyclohexane, pyridine, thiophene or furan ring which optionally bears up to 2 substituents independently selected from halogen, NO2, CN, OH, phenyl, C1-4alkyl, C2-4alkenyl, polyfluoroC1-4alkyl, C3-4cycloalkyl, C3-6cycloalkylC1-4alkyl, C1-4alkoxy, C1-4alkoxyC1-4alkyl, polyfluoroC1-4alkoxy, C1-4alkylcarbonyl, polyfluoroC1-4alkylcarbonyl, C1-4alkoxycarbonyl, C1-4alkylthio, C1-4alkylsulfonyl, SO2NR2, CONR2 or NR2 where each R is independently H or C1-4alkyl;
• or two R10 groups attached to non-adjacent ring positions optionally complete a CH2 or CH2CH2 bridge.